Genetics, risk factors and COVID-19

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-385

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Dr. Stephen Burgess
  • Research Location

    United Kingdom
  • Lead Research Institution

    MRC Biostatistics Unit
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

How can we answer questions of causation ("what if?" questions) when we can't perform experiments directly? In the case of COVID-19, a typical causal question would look like this: what would happen if we prescribed people anti-inflammatory medications? Would it improve outcomes? While we can answer these questions definitively by performing a randomized trial, this approach is slow. With this outbreak, time is of the essence and there are many potential treatments to evaluate. Instead of performing the randomization ourselves, our approach is to exploit a randomization that nature has provided for us in genetics.